Ro 04-5595 hydrochloride

Discontinued Product

2005 has been discontinued.

View all NMDA Receptors products.
说明: GluN2B-selective NMDA antagonist
化学名: 1-[2-(4-Chlorophenyl)ethyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-7-isoquinolinol hydrochloride
纯度: ≥98% (HPLC)
说明书
引用文献 (1)
评论
文献 (5)

生物活性 for Ro 04-5595 hydrochloride

Ro 04-5595 hydrochloride is a selective antagonist for GluN2B (formally NR2B) containing NMDA receptors (Ki = 31 nM).

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

技术数据 for Ro 04-5595 hydrochloride

分子量 368.3
公式 C19H22ClNO2.HCl
储存 Desiccate at +4°C
纯度 ≥98% (HPLC)
CAS Number 64047-73-0
PubChem ID 46739
InChI Key NVIPBLQAFKRFSZ-UHFFFAOYSA-N
Smiles Cl.COC1=CC2=C(C=C1O)C(CCC1=CC=C(Cl)C=C1)N(C)CC2

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for Ro 04-5595 hydrochloride

参考文献 for Ro 04-5595 hydrochloride

参考文献是支持产品生物活性的出版物。

Mutel et al (1998) In vitro binding properties in rat brain of [3H] Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J.Neurochem. 70 214

按产品操作查看相关产品

查看全部 NMDA Receptor Antagonists

关键词: Ro 04-5595 hydrochloride, Ro 04-5595 hydrochloride supplier, Selective, NR2B, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Ro04-5595, hydrochloride, GluN2B, 2005, Tocris Bioscience

1 篇 Ro 04-5595 hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Ro 04-5595 hydrochloride 的部分引用包括:

Voyer (2017) Repeated ventral midbrain neurotensin injections sensitize to amphetamine-induced locomotion and ERK activation: A role for NMDA receptors Neuropharmacology 112 150 PMID: 27267684


Ro 04-5595 hydrochloride 的评论

目前没有该产品的评论。 Be the first to review Ro 04-5595 hydrochloride and earn rewards!

Have you used Ro 04-5595 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.